For Immediate Release

Chicago, IL – November 19, 2009 – Zacks Equity Research highlights CPFL Energia (CPL) as the Bull of the Day and The Medicines Company (MDCO) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Eastman Chemical Co.(EMN), Dow Chemical Company (DOW) and Dupont (DD).

Full analysis of all these stocks is available at http://at.zacks.com/?id=5506

Here is a synopsis of all five stocks:

Bull of the Day:

We are maintaining our Outperform rating on CPFL Energia (CPL). The company posted in-line results for the third quarter of 2009, despite non-recurring items.

The company's outlook for the medium-term remains positive, mainly considering the more relaxed monetary policy in Brazil and the growing demand for electricity, even though there is the still-difficult business environment around the world.

Finally, CPL has a solid dividend payout and its valuation

...

Eastman Chemical Co. (EMN) has raised its full year 2009 earnings guidance to $3.50 per share from the initial guidance of $2 to $3 per share, driven by an expected strong growth in its core business. The company is hoping to deliver about 20% or over $6 per share growth in annual earnings by 2012, as the economy recovers completely. The Zacks Consensus Estimate is pegged at $3.22 for 2009 and at 93 cents for the fourth quarter. Recently, Eastman’s close peers, Dow Chemical Company (DOW) and Dupont (DD) have also predicted strong growth in earnings. Eastman stands to benefit from its business restructuring and cost-cutting measures, which are expected to result in cost savings of more than $200 million for the full year 2009. Eastman’s earnings of $1.38 per share in the third quarter of 2009 had bettered the Zacks Consensus Estimate of ...

Dow Chemical Company (DOW) is planning to sell more non-core assets in 2010 to pay off debt from its $16.5 billion acquisition of rival Rohm and Haas in April of this year. It is planning further debt reductions of about $12 billion. Dow stated that it plans to lighten its debt load and achieve its financial targets ahead of schedule. The Rohm and Haas acquisition is proving to be positive for Dow, which is expected to consolidate higher-margin and higher-growth specialty businesses and reduce volatility in earnings and cash flow, going forward. Dow is aiming to nearly double margins and quadruple earnings per share while reducing debt in the coming years. The company has predicted earnings of $4 to $4.50 per share in 2012 (up from last year’s $1.82) to be achieved through a mix of growth synergies as well as restructuring and cost synergies. ...

Diversified chemical company Dow Chemical Company (DOW) has signed an agreement to sell its non-core Powder Coatings Business to Akzo Nobel N.V. (AKZOY), a leading producer of paints and coatings, based in Amsterdam, The Netherlands. Financial terms of the transaction were not disclosed. The transaction is expected to close by the second quarter of 2010, subject to customary closing conditions, including regulatory approvals.  Dow plans to use the proceeds from the transaction to repay debt, consistent with the company's de-leveraging plan. Dow plans to raise about $3.5 billion by divesting its non-core assets. For the Chemicals group Akzo Nobel, the deal will bring upgraded technological expertise and significant synergy potential for the Powder Coatings business, as well as enhance the company's position in the U.S.  The powder coatings activities were purchased by Dow earlier this year as part of its acquisition of Rohm & Haas. ...

Ei Dupont De Nemours Co.(DuPont) (DD) recently announced that it expects to generate about 10% growth in the top-line during 2009-2012. The chemical giant also plans to capture $1 billion in fixed cost productivity and $1 billion in working capital productivity gains during the 2010-2012.

On average, DuPont expects to deliver almost 20% year-over-year growth in earnings per share between 2009 and 2012. Despite an expected decline in pharmaceutical royalties after expiry of patents in 2010, DuPont expects to grow earnings between $2.10 and $2.40 per share in the year. The company has also reaffirmed its full-year 2009 earnings outlook of $1.95 to $2.05 per share, excluding significant items, which are estimated to be $0.15 per share for full-year 2009 or $1.80 to $1.90 per share on a reported basis. It had previously forecasted earnings of $1.70 to $2.10 a share. DuPont expects improving demand in key markets, as

...

Chemical giant EI DuPont de Nemours & Company (DD) reported third quarter 2009 earnings of 45 cents, beating the Zacks Consensus Estimate of 33 cents, helped by significant cost cuts and lower raw material, energy and freight expenses. Cost cuts have boosted Du Pont’s third-quarter pretax earnings by about $300 million, bringing cost reductions year to date to $900 million. The company's full-year goal is $1 billion. Raw material, energy and freight costs were 12% lower than the previous year levels, and Du Pont expects these costs for full year 2009 to be about 5 to 6 % lower than 2008. However, revenue in the quarter slipped 18% to $6.16 billion reflecting a 12% decline in volumes and a 2% fall in prices. Sales in the Coatings & Color Technologies segment decreased 16% to $1.5 billion on continued weakness in motor vehicle markets while sales in ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday October 20, 2009

DrStockPick.com Stock Report!

**************************************************************

Cavitation Technologies, Inc.  (OTC Bulletin Board: CVAT) has signed Miura Engineering Co., Ltd. Tokyo, Japan (www.miura21.co.jp) as its new agent to serve markets in Japan for CTI’s Nano-Cavitation Process Systems. Miura is a leading Engineering Company specialized in Edible Oil Processing Plants in the Far East.

Speakeasy (www.speakeasy.net), a Best Buy company (NYSE: BBY), today introduced EasyVoice® Mobile for iPhone(TM), published by JNSoftware LLC. EasyVoice Mobile brings the savings and flexibility of Speakeasy Hosted Voice

...

Dow Chemical Co. (...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday September 29, 2009

DrStockPick.com Stock Report!

PFE, PWRM, TXN, CSRH, AA, CVAT, DOW

**************************************************************

PFE, Pfizer Inc.

PFE is the world’s premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals.

China’s Ministry of Commerce has approved PFE’s pending acquisition of Wyeth. The Ministry’s decision includes PFE’s commitment to divest certain animal health assets in China.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways,

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

 

Wednesday September 16, 2009

DrStockPick.com Stock Report!

AMKR, PWRM, NWMT, CVAT, CSRH, GTXO , AQNM, TSPG, DOW

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer

...